Research records indexed for ARA 290
This page carries 12 of the 26 records that the literature query returned for ARA 290, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index, and the 14 records it does not carry are not represented here. Every row resolves to a real identifier and names the study model, so no finding reads as a human claim by default. The compound page is ARA 290.
Indexed records
| Record | Year | Study type | Model | n as stated | What it reported |
|---|---|---|---|---|---|
| Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management pmid:42635865 | 2026 | Review | other | Not stated | Indexed as review. compound named in the abstract, not the title. study model from MeSH "Animals" with no rodent species heading. subject headings: Thymosin; Peptides; Regenerative Medicine; Pain Management; Chronic Pain. |
| Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db mice pmid:41933665 | 2026 | Journal Article | rodent | Not stated | Indexed as journal article. compound named in the abstract, not the title. study model from MeSH "Mice, Inbred C57bl". subject headings: Mice, Inbred C57BL; Diabetes Mellitus, Type 2; Reversal Learning; Executive Function; Cognitive Dysfunction. |
| Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways pmid:36085231 | 2023 | Journal Article | other | Not stated | Indexed as journal article. study model from MeSH "Humans" with no interventional publication type. subject headings: Kidney; Inflammation; Cisplatin; Reactive Oxygen Species; Tumor Necrosis Factor-Alpha. |
| Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression pmid:34343617 | 2022 | Research Support, Non-U.S. Gov't | rodent | Not stated | Indexed as research support, non-u.s. gov't. study model from MeSH "Mice, Transgenic". subject headings: Monocytes; Mice, Transgenic; Alzheimer Disease; Disease Models, Animal; Amyloid Beta-Protein Precursor. |
| An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress pmid:32335150 | 2020 | Journal Article | other | Not stated | Indexed as journal article. study model from MeSH "Humans" with no interventional publication type. subject headings: Cell Line; DNA Damage; Reactive Oxygen Species; Doxorubicin; Superoxide Dismutase. |
| A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets pmid:26683514 | 2016 | Research Support, Non-U.S. Gov't | rodent | Not stated | Indexed as research support, non-u.s. gov't. study model from MeSH "Mice, Inbred C57bl". subject headings: Liver; Islets Of Langerhans; Cells, Cultured; Macrophages; Mice, Inbred C57BL. |
| ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception pmid:26774587 | 2016 | Journal Article | rodent | Not stated | Indexed as journal article. study model from MeSH "Mice, Inbred C57bl". subject headings: Mice, Inbred C57BL; Capsaicin; Oligopeptides; Analgesics; Drug Evaluation, Preclinical. |
| ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes pmid:25387363 | 2015 | Clinical Trial, Phase II, Controlled Clinical Trial | human trial | Not stated | Indexed as clinical trial, phase ii, controlled clinical trial. study model from MeSH "Humans" with publication type "clinical trial, phase ii". subject headings: Diabetic Neuropathies; Diabetes Mellitus, Type 2; Lipids; Oligopeptides; Erythropoietin. |
| ARA 290 for treatment of small fiber neuropathy in sarcoidosis pmid:24555851 | 2014 | Review | other | Not stated | Indexed as review. study model from MeSH "Animals" with no rodent species heading. subject headings: Neuralgia; Erythromelalgia; Sarcoidosis; Oligopeptides; Analgesics. |
| ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response pmid:24529189 | 2014 | Research Support, Non-U.S. Gov't, research-article | rodent | Not stated | Indexed as research support, non-u.s. gov't, research-article. study model from MeSH "Rats". subject headings: Spinal Cord; Posterior Horn Cells; Microglia; Sciatic Nerve; Rats, Sprague-Dawley. |
| ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density pmid:24136731 | 2013 | Research Support, Non-U.S. Gov't, research-article | human trial | Not stated | Indexed as research support, non-u.s. gov't, research-article. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Nerve Fibers; Cornea; Erythromelalgia; Sarcoidosis; Oligopeptides. |
| Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study pmid:23168581 | 2012 | research-article, Randomized Controlled Trial | human trial | Not stated | Indexed as research-article, randomized controlled trial. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Nervous System Diseases; Sarcoidosis; Peptides; Placebos; Pilot Projects. |
Where this page sits
Compound page: ARA 290. Class: Tissue repair peptides.
Retrieved 2026-10-12.
Sources
- PubChem Compound Summary for CID 91810664, Cibinetide. PubChem, National Library of Medicine (2026). pubchem:91810664
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:ara-290
- ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Molecular pain (2014). pmid:24529189
- A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets. Transplantation (2016). pmid:26683514
- An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress. Toxicology in vitro : an international journal published in association with BIBRA (2020). pmid:32335150
- Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression. Brain, behavior, and immunity (2022). pmid:34343617
- Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Molecular medicine (Cambridge, Mass.) (2012). pmid:23168581
- ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Molecular medicine (Cambridge, Mass.) (2013). pmid:24136731
- ARA 290 for treatment of small fiber neuropathy in sarcoidosis. Expert opinion on investigational drugs (2014). pmid:24555851
- ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Molecular medicine (Cambridge, Mass.) (2015). pmid:25387363
- Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Investigative ophthalmology & visual science (2017). pmid:28475703
- Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis. Scientific reports (2017). pmid:29026145
- The vasoreparative potential of endothelial colony-forming cells in the ischemic retina is enhanced by cibinetide, a non-hematopoietic erythropoietin mimetic. Experimental eye research (2019). pmid:30876881
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.